Cargando…
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Autores principales: | Dhere, Rajeev, Sethna, Vistasp, Malviya, Hitesh, Adhiseshan, Rajeshwari |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124258/ https://www.ncbi.nlm.nih.gov/pubmed/35482226 http://dx.doi.org/10.1007/s40121-022-00643-7 |
Ejemplares similares
-
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
por: Perdrizet, Johnna, et al.
Publicado: (2021) -
Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
por: Gomez, Jorge A., et al.
Publicado: (2022) -
A Response to: Letter to the Editor Regarding “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
por: Perdrizet, Johnna, et al.
Publicado: (2022) -
Response to Gomez et al.’s Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
por: Perdrizet, Johnna, et al.
Publicado: (2022) -
Development strategy and lessons learned for a 10-valent pneumococcal conjugate vaccine (PNEUMOSIL®)
por: Alderson, Mark R., et al.
Publicado: (2021)